latest news on glp 1 drugs Risks of Ozempic, other GLP-1 are at center of sweeping lawsuit that kicked off in Philadelphia How do new GLP-1 drugs

For immediate mental health crisis, call 999, contact NHS 111 (option 2), or call Samaritans on 116 123

Gutgesell RM et al ., 2024

As glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and newer dual- or tri-receptor agonists (incretin mimetics) redefine metabolic health management, oncology clinicians increasingly face questions about their use during and after active cancer treatment

A recent prospective case-control study in IIH highlighted deficits in executive function and attention, which were reversible with reductions of ICP [6]

GLP-1 receptor agonists also have favourable effects on albuminuria and may slow eGFR decline , though the evidence for hard renal outcomes is less robust than for SGLT2 inhibitors

Protecting that investment with appropriate treatment duration planning makes the extended course worthwhile for most patients